Literature DB >> 18558368

Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?

Reinhard Schwartz-Albiez1, Simon Laban, Stefan Eichmüller, Michael Kirschfink.   

Abstract

Healthy individuals may contain in their peripheral blood antibodies which are able to destroy human tumour cells mediated either by complement-dependent cytotoxicity or by apoptosis. The largest proportion of these antibodies is of IgM isotype and directed against distinct tumour associated carbohydrate epitopes. Although the origin of these antibodies is not clear they seem to belong to the class of natural antibodies because they are not affinity matured and are encoded by distinct germ-line restricted gene families. It is most likely that this class of natural antibodies has in vivo an anti-tumour protective effect which may contribute to so-called tumour surveillance. On the other hand malignant tumour cells exert mechanisms to counteract such an antibody attack. These comprise soluble factors as well as cell surface expressed membrane complement regulatory proteins (mCRP). Further studies are needed to elucidate molecular mechanisms leading to either tumour destruction induced by natural antibodies or to overcome the protective strategies of the tumour against antibody attack.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558368     DOI: 10.1016/j.autrev.2008.03.012

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  16 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

2.  Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.

Authors:  Yilai Wang; Zhaoping Yan; Yile Huang; Cailing Qiu; Xiangyun Chen; Ying Hu; Qingyong Meng; Jun Wei
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 3.  Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation.

Authors:  R Schwartz-Albiez; R C Monteiro; M Rodriguez; C J Binder; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 4.  Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Authors:  Mohan S Maddur; Sébastien Lacroix-Desmazes; Jordan D Dimitrov; Michel D Kazatchkine; Jagadeesh Bayry; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 5.  A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics.

Authors:  Haike Ghazarian; Brian Idoni; Steven B Oppenheimer
Journal:  Acta Histochem       Date:  2010-03-02       Impact factor: 2.479

6.  Natural antibody - Biochemistry and functions.

Authors:  Ali Seyar Rahyab; Amit Alam; Aricka Kapoor; Ming Zhang
Journal:  Glob J Biochem       Date:  2011

Review 7.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

8.  Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Authors:  Silvia Catellani; Ivana Pierri; Marco Gobbi; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

9.  Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  B-1 cell immunoglobulin directed against oxidation-specific epitopes.

Authors:  Dimitrios Tsiantoulas; Sabrina Gruber; Christoph J Binder
Journal:  Front Immunol       Date:  2013-01-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.